CCND1 and ovarian carcinoma: It has been reported that CCND1 is involved in the mechanism associated with CDK4/6 cell cycle kinase inhibitor resistance in estrogen receptor-positive breast cancer24 while silencing CCND1 was found to increase the ovarian cancer cells' susceptibility to olaparib medicines25.